Gentofte, Denmark

Daniel Aaskov


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Daniel Aaskov in Biostable Glucose Permeable Polymers

Introduction

Daniel Aaskov is an innovative inventor based in Gentofte, Denmark. He has made significant contributions to the field of biomedical engineering, particularly in the development of materials for implantable devices. His work focuses on creating solutions that enhance the functionality and longevity of medical sensors.

Latest Patents

Daniel Aaskov holds a patent for a biostable glucose permeable polymer. This innovative polymer is particularly useful in the development of implantable glucose sensors. The polymer exhibits advantageous characteristics, such as resistance to hydrolytic cleavage and degradation, which ensures long-term stability of sensors in vivo. The invention encompasses the polymer composition, sensor systems derived from this composition, and methods for their production and application.

Career Highlights

Aaskov is currently associated with Medtronic Minimed, Inc., a leading company in the field of diabetes management and technology. His work at Medtronic has allowed him to focus on advancing sensor technology, which is crucial for effective diabetes care. His contributions have the potential to improve the quality of life for individuals relying on glucose monitoring systems.

Collaborations

Daniel Aaskov has collaborated with notable colleagues, including Tri T Dang and Henrik Egesborg. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of biomedical engineering.

Conclusion

Daniel Aaskov's work in developing biostable glucose permeable polymers represents a significant advancement in medical technology. His contributions are poised to enhance the performance and reliability of implantable glucose sensors, ultimately benefiting patients who depend on these critical devices.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…